Carl Zeiss buys Laser Diagnostic Technologies for its complementary glaucoma technology
This article was originally published in Clinica
The US arm of Jena, Germany-based Carl Zeiss Meditec is to expand its glaucoma diagnosis offering through the acquisition of Laser Diagnostic Technologies (LDT), of San Diego, California. Carl Zeiss intends to close the transaction for an undisclosed sum within 30-45 days.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.